| Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
|
| Notes: |
Hameatology/Oncology related Prescribing Guidance
Please see our Prescribing Guidelines page for all prescribing guidance relating to this chapter.
Haematology/Oncology related Shared Care Agreements
Please see our Shared Care Agreements page for all shared care agreements (SCAs) relating to this chapter.
|
|
|
| Details... |
| 08.01.05 |
Other antineoplastic drugs |
|
|
| 08.01.05 |
Amsacrine |
|
|
| 08.01.05 |
Arsenic trioxide |
|
|
| 08.01.05 |
Bortezomib |
|
|
| 08.01.05 |
Brentuximab vedotin |
|
|
| 08.01.05 |
Cetuximab |
|
|
| 08.01.05 |
Dacarbazine and Temozolomide |
|
|
| 08.01.05 |
Erlotinib |
|
|
| 08.01.05 |
Hydroxycarbamide |
|
|
| 08.01.05 |
Ipilimumab |
|
|
| 08.01.05 |
Pentostatin |
|
|
| 08.01.05 |
Platinum compounds |
|
|
| 08.01.05 |
Procarbazine |
|
|
| 08.01.05 |
Protein kinase inhibitors |
|
|
Afatinib
(Tablets)
|
Formulary
 
|
- 20mg, 30mg, 40mg and 50mg tablets
|
 NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
|
Cabozantinib
(Oral)
|
Formulary
|
|
NICE TA463 : Cabozantinib for previously treated advanced renal cell carcinoma
NICE TA516: Cabozantinib for treating medullary thyroid cancer
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
|
Crizotinib
(Tablets)
|
Formulary
|
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance
|
Dasatinib
(Tablets)
|
Formulary
|
- 20mg, 50mg, 80mg, 100mg and 140mg tablets
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Entrecitinib
(Capsules)
|
Formulary
|
- 100mg, 200mg capsules
- Use in line with NICE TA643 and 644
|
NICE TA 644 Entrectinib for treating NTRK fusion-positive solid tumours
NICE TA643 Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
|
Everolimus
(Afinitor®)
(Tablets)
|
Formulary
|
- 2.5mg, 5mg and 10mg tablets
- Ensure correct brand is prescribed.
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
|
Everolimus
(Votubia®)
(Tablets)
|
Formulary
|
- Only at RUH
- 2.5mg, 5mg and 10mg tablets
- Ensure correct brand is supplied
- To be prescribed by specialist centres in accordance with NHSE commissioning policies
|
 Clinical Commissioning Policy: Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (ages 2 years and above)
Clinical Commissioning Policy: Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (ages 2 years and above)
|
Gefitinib
(Tablets)
|
Formulary
|
|
NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
|
Gilteritinib
(Tablets)
|
Formulary
|
- 40mg tablets
- Use in line with NICE TA642
|
NICE TA642 Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
|
Imatinib
(Gilvec®)
(Tablets)
|
Formulary
|
- 100mg and 400mg tablets
- Ensure correct brand supplied
|
NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
|
Imatinib (Generic)
(Tablets)
|
Formulary
|
- 100mg and 400mg tablets
- Also for treatment of Philadelphia Positive Guidelines ALL as per BCSH Guidelines
|
NICE TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Nilotinib
(Capsules)
|
Formulary
|
|
NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Pazopanib
(Tablets)
|
Formulary
|
|
NICE TA215: Pazopanib in renal cell cancer
|
Regorafenib
(Tablets)
|
Formulary
|
|
NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
|
Sorafenib
(Tablets)
|
Formulary
|
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
|
Sunitinib
(Capsules)
|
Formulary
|
- 12.5mg, 25mg and 50mg capsules
|
NICE TA169: Renal cell carcinoma - sunitinib
NICE TA179: Gastrointestinal stromal tumours - sunitinib
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
|
Tivozanib
(Capsules)
|
Formulary
|
- 890microgram and 1340microgram capsules
|
NICE TA512: Tivozanib for treating advanced renal cell carcinoma
Tivozanib for treating advanced renal cell carcinoma
|
Vemurafenib
(Tablets)
|
Formulary
|
|
NICE TA269: Vemurafenib for treating malignant melanoma
|
| 08.01.05 |
Taxanes |
|
|
| 08.01.05 |
Topoisomerase I inhibitors |
|
|
| 08.01.05 |
Trabectedin |
|
|
| 08.01.05 |
Trastuzumab |
|
|
| 08.01.05 |
Tretinoin |
|
|
| 08.01.05 |
Vismodegib |
|
|
| .... |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
High Cost Drug Approval System |
|
Traffic Light Status Information
|
|
|
